50 results about "Recombinant virus vaccine" patented technology

The present inventors developed 5a / 2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 5a reference strain SA13. Compared to the J6 / JFH control virus, after transfection of in vitro transcripts in Huh7.5 cells, production of infectious viruses was delayed. However, in subsequent viral passages efficient spread of infection and HCV RNA titers as high as for J6 / JFH were obtained. Infectivity titers were at all time points analyzed comparable to J6 / JFH control virus. Sequence analysis of recovered 5a / 2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in p7, NS2 and / or NS3. Infectivity of the 5a / 2a viruses was CD81 and SR-BI dependant, and the recombinant viruses could be neutralized by chronic phase sera from patients infected with genotype 5a. Conclusion: The developed 5a / 2a viruses provide a robust in vitro tool for research in HCV genotype 5, including vaccine studies and functional analyses of an increasingly important genotype in South Africa and Europe.

The invention discloses an adenovirus vector vaccine for preventing SARS-CoV-2 infection. The vaccine comprises a nucleic acid sequence as shown in SEQ ID NO: 1. According to a plurality of embodiments of the invention, the S protein nucleic acid sequence contained in the vaccine is easy to express in human cells, and generation of more S proteins can be induced, so the vaccine is expected to be used as a recombinant virus vaccine for preventing SARS-CoV-2 infection. According to a plurality of embodiments of the invention, the vaccine has good security.

The invention relates to a virus vaccine A-NDV-LX / 14 for a newcastle disease, which is a recombinant of expressed genes VII F and HN, and the preservation number is CGMCCNO: 3844. After two weeks of the constructed virus A-NDV-LX / 14 immunity test on chicken, the average potency of the serum HI is 27. After four days of eliminating toxic material with immune group LaSota, the virus isolation ratesof SPF chicken laryngotracheal and cloacal swab samples are 10 percent and 30 percent respectively, and the virus isolation rates of chicken laryngotracheal and cloacal swab samples are 40 percent and 20 percent respectively. After four days of eliminating toxic material with immune group V4, the virus isolation rates of SPF chicken laryngotracheal and cloacal swab samples are 30 percent and 10 percent respectively, and the virus isolation rates of chicken laryngotracheal and cloacal swab samples are 30 percent and 20 percent respectively. Compared with traditional vaccine, more effective immune protection can be provided by the recombinant virus vaccine.